NCT00207779

Prevention of Catheter-Related Bloodstream Infection in Patients With Haemato-Oncological Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Centre National de Greffe de Moelle Osseuse · Other Government
• Sex: All
• Age: 4 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

We, the researchers at Centre National de Greffe de Moelle Osseuse, have shown in a randomised study (in press), that a low dose of unfractionated heparin (100 IU/kg/daily) was safe and effective to prevent catheter-related bloodstream infection in patients with haemato-oncological disease. The aim of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with haemato-oncological disease: * Group A: heparin impregnated catheters * Group B: low-dose unfractionated heparin (100 IU/kg/daily)

Detailed description

Studies have shown that catheter-related infection may be due to fibrin deposition associated with catheters. Interventions designed to decrease fibrin deposition and thrombus formation have the potential to reduce catheter-related infections. Seven randomised studies have been performed to assess the safety and efficacy of heparin (either as an infusion or bonded to central venous catheter) on central venous catheter-related bloodstream infections. Although a meta-analysis of 4 studies looking at heparin either as an infusion or bonded to central venous catheter showed a strong trend for a reduction in catheter-related bloodstream infection with the use of heparin, these studies used variable definitions of catheter-related infections. We have shown in a randomised study (in press), that low dose of unfractionated heparin (100 IU/kg/daily) was safe and effective to prevent catheter-related bloodstream infection in patients with haemato-oncological disease. The aim of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with haemato-oncological disease: * Group A: heparin impregnated catheters * Group B: low-dose unfractionated heparin (100 IU/kg/daily)

Conditions

• Infection

Interventions

Type	Name	Description
DEVICE	heparin impregnated central venous catheters

Timeline

• Start date: 2005-05-01
• Completion: 2005-08-01
• First posted: 2005-09-21
• Last updated: 2007-09-20

Locations

1 site across 1 country: Tunisia